ITGB1 adjacent tumor promoting long non-coding RNA (IATPR)

ITGB1 adjacent tumor promoting long non-coding RNA (IATPR; also known as linc-ITGB1 or TCONS_00018476) is a long non-coding RNA transcribed from a genomic locus adjacent to the ITGB1 gene on human chromosome 10. IATPR/linc-ITGB1 has been shown to be overexpressed in several malignancies, including colorectal cancer, gallbladder cancer, breast cancer, and hepatocellular carcinoma[2][4][10][12]. Functional studies demonstrate that higher expression of IATPR is associated with increased cancer cell proliferation, migration, invasion, and worse patient outcomes. Silencing this lncRNA inhibits tumor cell migration and invasion, and appears to affect tumor behavior partly by modulating genes such as BDNF and pathways relevant to epithelial-to-mesenchymal transition. It is classified as a long intergenic non-coding RNA (lincRNA) and is not a protein-coding gene, but may serve as a regulatory RNA influencing oncogenic processes. There are currently no known drugs that directly target IATPR, though it is considered a potential therapeutic target for future RNA-based therapies in oncology[2][4][10][12].

Other names

linc-ITGB1TCONS_00018476

Not applicable; as a non-coding RNA, it is not a classical drug-binding protein. Hypothetical mechanism for potential oligonucleotide or RNA-targeting: gene silencing via RNA interference or antisense oligonucleotides